Last week Helicos BioSciences posted a few more details on its shift toward diagnostics (and away from the research market) that was announced in May:
Helicos believes that the HeliScope Sequencer will have utility across a broad array of molecular diagnostic (MDx) tests. Initially, Helicos is developing a MDx test that will identify gene mutations indicative of a woman’s increased risk of developing hereditary breast or ovarian cancer. This test is currently scheduled to launch during the second quarter of 2011.
Helicos originally was shooting to be the first to deliver a $1000K genome, but given the increasingly ferocious competition in the area of low-cost sequencing, it remains to be seen what areas of the market Helicos may capture.
Related posts:
